What is AbbVie's deferred tax assets?

AbbVie (ABBV) reported deferred tax assets of $137.00M in Q1 2026.

How has AbbVie's deferred tax assets changed year-over-year?

AbbVie's deferred tax assets decreased by 94.7% year-over-year, from $2.58B to $137.00M.

What is the long-term trend for AbbVie's deferred tax assets?

Over 5 years (2020 to 2025), AbbVie's deferred tax assets has grown at a -8.1% compound annual growth rate (CAGR), from $3.65B to $2.39B.

What does deferred tax assets mean?

Future tax savings that the company expects to realize due to past accounting differences or tax losses.

Non-Current Assets

Deferred Tax Assets

AbbVie Deferred Tax Assets decreased by 94.3% to $137.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.7%, from $2.58B to $137.00M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows a downward trend with a -8.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Assets

CategoryEfficiency

SignalHigher is better

VolatilityModerate

First reportedQ4 2014

Last reportedQ1 2026May 8, 2026

How to read this metric

An increase can signal future tax efficiency or the utilization of past losses, while a decrease may indicate the realization of those benefits.

Detailed definition

These are assets on the balance sheet that represent future tax savings resulting from temporary differences between the...

Peer comparison

Common in large, capital-intensive companies; peers with significant R&D spending often have large deferred tax assets from tax credits.

Metric ID: deferred_tax_assets

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$3.66B	$3.60B	$3.01B	$2.83B	$2.26B	$1.97B	$2.19B	$2.11B	$2.12B	$2.04B	$1.95B	$2.72B	$2.73B	$2.75B	$2.58B	$2.58B	$2.55B	$2.48B	$2.39B	$137.00M
QoQ Change	—	-1.6%	-16.5%	-5.9%	-20.3%	-12.5%	+11.1%	-3.7%	+0.7%	-3.8%	-4.5%	+39.4%	+0.1%	+0.8%	-6.2%	+0.1%	-1.1%	-2.9%	-3.7%	-94.3%
YoY Change	—	—	—	—	-38.4%	-45.3%	-27.2%	-25.5%	-5.8%	+3.7%	-10.9%	+29.0%	+28.3%	+34.5%	+32.1%	-5.1%	-6.3%	-9.8%	-7.4%	-94.7%

Range$137.00M – $3.66B

CAGR-49.9%

Avg YoY Growth-9.3%

Median YoY Growth-6.8%

Current Streak4 quarters decline

Deferred Tax Assets at Other Companies

Eli LillyLLY View metric

PfizerPFE View metric

McKessonMCK View metric

Bristol-Myers SquibbBMY View metric

AbbottABT View metric

Merck & Co.MRK View metric

Frequently Asked Questions

What is AbbVie's deferred tax assets?: AbbVie (ABBV) reported deferred tax assets of $137.00M in Q1 2026.
How has AbbVie's deferred tax assets changed year-over-year?: AbbVie's deferred tax assets decreased by 94.7% year-over-year, from $2.58B to $137.00M.
What is the long-term trend for AbbVie's deferred tax assets?: Over 5 years (2020 to 2025), AbbVie's deferred tax assets has grown at a -8.1% compound annual growth rate (CAGR), from $3.65B to $2.39B.
What does deferred tax assets mean?: Future tax savings that the company expects to realize due to past accounting differences or tax losses.